Page last updated: 2024-11-02

pirenzepine and Chemical Dependence

pirenzepine has been researched along with Chemical Dependence in 9 studies

Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Research Excerpts

ExcerptRelevanceReference
"The objective of this study was to evaluate the efficacy and safety of olanzapine in patients with schizophrenia and comorbid substance abuse disorders."9.09Olanzapine treatment for patients with schizophrenia and substance abuse. ( Hilligoss, NM; Johnson, CG; Littrell, KH; Peabody, CD; Petty, RG, 2001)
"The objective of this study was to evaluate the efficacy and safety of olanzapine in patients with schizophrenia and comorbid substance abuse disorders."5.09Olanzapine treatment for patients with schizophrenia and substance abuse. ( Hilligoss, NM; Johnson, CG; Littrell, KH; Peabody, CD; Petty, RG, 2001)
" This article will describe the potential use of the atypical antipsychotics, especially olanzapine, for affective mood disturbances in schizophrenia, psychotic depression and mania, first-break schizophrenia, comorbid schizophrenia and substance abuse disorders, dementia in the elderly and those with late-onset schizophrenia, and behavioral problems in patients with mental retardation or developmental delays."4.79Olanzapine and the new generation of antipsychotic agents: patterns of use. ( Glazer, WM, 1997)
" The patient was previously treated with olanzapine and developed priapism, which required emergency medical treatment."3.72Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report. ( Weisman, RL, 2003)
"Although life prevalence of substance use disorders among patients with schizophrenia is close to 50%, few studies have been carried out to date to identify an integrated pharmacological treatment for this comorbidity."2.42Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. ( Potvin, S; Roy, JY; Stip, E, 2003)
"This study determines the extent of substance abuse in a treatment-resistant population and assesses the response of this population to olanzapine treatment."1.30Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. ( Conley, RR; Gale, EA; Kelly, DL, 1998)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (33.33)18.2507
2000's6 (66.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mechanic, JA1
Maynard, BT1
Holloway, FA1
Potvin, S1
Stip, E1
Roy, JY1
Weisman, RL1
Sattar, SP1
Grant, K1
Bhatia, S1
Petty, F1
Glazer, WM1
Conley, RR1
Kelly, DL1
Gale, EA1
Lindenmayer, JP1
Patel, R1
Solhkhah, R1
Finkel, J1
Hird, S1
Littrell, KH1
Petty, RG1
Hilligoss, NM1
Peabody, CD1
Johnson, CG1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia[NCT00156715]Phase 423 participants (Actual)Interventional2004-03-31Completed
Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients[NCT00780702]Phase 141 participants (Actual)Interventional2008-05-08Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Clinical Symptoms

The main outcome measure of clinical symptoms was the Positive and Negative Symptoms Scale. This is a 30 item scale for assessing patients diagnosed with schizophrenia. Each item is rated on a 1 (absent) to 7 (extreme) scale. The minimum total score is 30 and the maximum is 210. (NCT00156715)
Timeframe: 12 Weeks

InterventionUnits on a scale (Mean)
QUET65.5

Mean Number of Drinking Days Per Week

Timeline Follow-back (TLFB) procedure was used at screening and baseline to establish current substance use, and it was also used weekly during the course of the study to assess continued alcohol and other substance use. TLFB cosisted of using a calendar and sasking participants to report alcohol and other drug use since last visit. At the screening visit, the TLFB was done for the four weeks prior to the visit. (NCT00156715)
Timeframe: 12 Weeks

InterventionDrinking Days per Week (Mean)
QUET2.7

Reviews

2 reviews available for pirenzepine and Chemical Dependence

ArticleYear
Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses.
    International clinical psychopharmacology, 2003, Volume: 18, Issue:3

    Topics: Affect; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Cognition; Comorbi

2003
Olanzapine and the new generation of antipsychotic agents: patterns of use.
    The Journal of clinical psychiatry, 1997, Volume: 58 Suppl 10

    Topics: Antipsychotic Agents; Benzodiazepines; Child; Comorbidity; Dementia; Depressive Disorder; Developmen

1997

Trials

2 trials available for pirenzepine and Chemical Dependence

ArticleYear
Potential use of olanzapine in treatment of substance dependence disorders.
    Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:4

    Topics: Alcoholism; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cocaine-Related Disorders; Huma

2003
Olanzapine treatment for patients with schizophrenia and substance abuse.
    Journal of substance abuse treatment, 2001, Volume: 21, Issue:4

    Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine

2001

Other Studies

5 other studies available for pirenzepine and Chemical Dependence

ArticleYear
Treatment with the atypical antipsychotic, olanzapine, prevents the expression of amphetamine-induced place conditioning in the rat.
    Progress in neuro-psychopharmacology & biological psychiatry, 2003, Volume: 27, Issue:1

    Topics: Amphetamine; Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Central Nervous Sys

2003
Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report.
    International journal of psychiatry in medicine, 2003, Volume: 33, Issue:1

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Black or African American; Contraindications; Diagnosi

2003
Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.
    Schizophrenia research, 1998, Sep-07, Volume: 33, Issue:1-2

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Illicit Drugs; Male; Middle Aged; Olan

1998
Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.
    Schizophrenia research, 1998, Sep-07, Volume: 33, Issue:1-2

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Illicit Drugs; Male; Middle Aged; Olan

1998
Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.
    Schizophrenia research, 1998, Sep-07, Volume: 33, Issue:1-2

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Illicit Drugs; Male; Middle Aged; Olan

1998
Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.
    Schizophrenia research, 1998, Sep-07, Volume: 33, Issue:1-2

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Illicit Drugs; Male; Middle Aged; Olan

1998
Olanzapine-induced ketoacidosis with diabetes mellitus.
    The American journal of psychiatry, 1999, Volume: 156, Issue:9

    Topics: Antipsychotic Agents; Antisocial Personality Disorder; Benzodiazepines; Diabetes Mellitus; Diabetic

1999
Possible risperidone-induced visual hallucinations.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2000, Volume: 39, Issue:9

    Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diagnosis, Du

2000